📰 Yi Lin News
Yi Lin News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Yi Lin. Real-time updates on events, politics, business and more.
February 19, 2024
Today (2/19) the solar term enter "Rain". Chiu Yenlung, an international expert in Feng Shui and numerology, reminds us that this year's rain solar term is very special. It is a watershed in destiny..
December 18, 2023
How the NASA-lead SABERS initiative is advancing the battery technology needed to support electric flight.
October 19, 2023
Yi Lin, MD, PhD, discusses findings from the primary analysis of the phase 1/2 CARTITUDE-1 trial of the BCMA-targeting CAR T-cell therapy ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.
September 8, 2023
Minimal residual disease negativity sustained for 6 months or longer with ciltacabtagene autoleucel prolonged duration of response and progression-free survival compared with minimal residual disease negativity sustained for less than 6 months in patients with heavily pretreated relapsed/refractory multiple myeloma.
September 7, 2023
Yi Lin, MD, PhD, discusses the patient characteristic for those with relapsed/refractory multiple myeloma who experienced sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel during the phase 1/2 CARTITUDE-1 trial.
August 22, 2023
NASA's SABERS initiative reveals a new solid-state battery using sulfur and selenium, presenting an efficient alternative for modern aviation.
June 6, 2023
Hong Kong-listed casino operator and developer NagaCorp Ltd, known for its flagship NagaWorld integrated resort in Phnom Penh, on June 4 announced that it has moved the $3.5 billion Naga 3 project’s planned completion date from September 30, 2025 to exactly four years later, in a bid to cut capital expenditure (capex) amid global economic concerns.
May 11, 2023
Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma (RRMM) from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from
May 11, 2023
Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from... | May 11, 2023
May 11, 2023
First disclosure from Phase 3 COMMANDS study, selected for both ASCO’s official press program and EHA’s plenary session, highlights potential of Reblozyl as first-line treatment of... | May 11, 2023